{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:58:19Z","timestamp":1791669499159,"version":"4.3.4"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ajo.2025.09.050","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T23:02:47Z","timestamp":1759359767000},"page":"502-515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Management of Retinopathy of Prematurity in the Anti-VEGF Era: Consensus and Recommendations From the Taiwan Pediatric Retina (TPR) Group"],"prefix":"10.1016","volume":"281","author":[{"given":"Tso-Ting","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0100-9341","authenticated-orcid":false,"given":"Yen-Chih","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Chu","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4777-5343","authenticated-orcid":false,"given":"Margaret Ming-Chih","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9398-1316","authenticated-orcid":false,"given":"Ning-Yi","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"San-Ni","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Bai","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hung","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2606-8540","authenticated-orcid":false,"given":"Hui-Ju","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Ling","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Hsun","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Ting","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3760-7255","authenticated-orcid":false,"given":"Wei-Chi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ajo.2025.09.050_bib0001","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.ophtha.2023.04.004","article-title":"Causes of Childhood Blindness in the United States Using the IRIS(R) Registry (Intelligent Research in Sight)","volume":"130","author":"Lim","year":"2023","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2025.09.050_bib0002","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3061","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.ajo.2025.09.050_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.earlhumdev.2023.105715","article-title":"UK screening and treatment of retinopathy of prematurity Updated 2022 Guidelines","volume":"177-178","author":"Wilkinson","year":"2023","journal-title":"Early Hum Dev"},{"key":"10.1016\/j.ajo.2025.09.050_bib0004","doi-asserted-by":"crossref","DOI":"10.1038\/s41433-021-01543-9","article-title":"The UK practice of Anti-VEGF therapy for treatment of retinopathy of prematurity","author":"Ahmed","year":"2021","journal-title":"Eye"},{"key":"10.1016\/j.ajo.2025.09.050_bib0005","article-title":"Systematic review of the guidelines for retinopathy of prematurity","author":"Kosciolek","year":"2022","journal-title":"Eur J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2025.09.050_bib0006","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.ophtha.2022.07.009","article-title":"Practice patterns and outcomes of intravitreal anti-vegf injection for retinopathy of prematurity: an international multicenter study","volume":"129","author":"Patel","year":"2022","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2025.09.050_bib0007","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-0034-1376389","article-title":"Using WINROP as an adjuvant screening tool for retinopathy of prematurity in southern Taiwan","volume":"30","author":"Ko","year":"2015","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajo.2025.09.050_bib0008","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ajo.2021.11.007","article-title":"Validation of the postnatal growth and retinopathy of prematurity screening criteria in a taiwanese cohort","volume":"237","author":"Huang","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"10208","key":"10.1016\/j.ajo.2025.09.050_bib0009","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ajo.2025.09.050_bib0010","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jama.2022.10564","article-title":"Effect of Intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: the FIREFLEYE randomized clinical trial","volume":"328","author":"Stahl","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ajo.2025.09.050_bib0011","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaophthalmol.2019.4517","article-title":"Validation of the postnatal growth and retinopathy of prematurity screening criteria","volume":"138","author":"Binenbaum","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.09.050_bib0012","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamaophthalmol.2019.4502","article-title":"Individual risk prediction for sight-threatening retinopathy of prematurity using birth characteristics","volume":"138","author":"Pivodic","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2025.09.050_bib0013","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity, third edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2025.09.050_bib0014","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/IAE.0000000000003627","article-title":"Rate of and time to complete retinal vascularization in premature infants and associated factors","volume":"43","author":"Lai","year":"2023","journal-title":"Retina"},{"issue":"9","key":"10.1016\/j.ajo.2025.09.050_bib0015","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1097\/IAE.0000000000002684","article-title":"Ten-year epidemiology of retinopathy of prematurity treatment in Taiwan","volume":"40","author":"Kang","year":"2020","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.ajo.2025.09.050_bib0016","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-42432-3","article-title":"Variations in medical practice of retinopathy of prematurity among 8 Asian countries from an international survey","volume":"13","author":"Youn","year":"2023","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.ajo.2025.09.050_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2025.100224","article-title":"Controversies, consensuses and guidelines on modern cataract surgery by the academy of Asia-Pacific professors of ophthalmology (AAPPO)","volume":"14","author":"Srinivas","year":"2025","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"7","key":"10.1016\/j.ajo.2025.09.050_bib0018","first-page":"6267","article-title":"Differences in the attitude regarding retinopathy of prematurity screening programs among neonatologists and ophthalmologists in taiwan: a survey","volume":"65","author":"Lai","year":"2024","journal-title":"Invest Ophth Vis Sci"},{"key":"10.1016\/j.ajo.2025.09.050_bib0019","doi-asserted-by":"crossref","DOI":"10.1097\/IAE.0000000000002754","article-title":"Anatomical and functional results of intravitreal aflibercept monotherapy for type 1 retinopathy of prematurity: one-year outcomes","author":"Chen","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2025.09.050_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4565216","article-title":"Refractive and biometric outcomes in patients with retinopathy of prematurity treated with intravitreal injection of ranibizumab as compared with bevacizumab: a clinical study of correction at three years of age","volume":"2018","author":"Chen","year":"2018","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.09.050_bib0021","doi-asserted-by":"crossref","DOI":"10.1007\/s00417-022-05730-6","article-title":"Refractive status, biometric components, and functional outcomes of patients with threshold retinopathy of prematurity: systemic review and a 17-year longitudinal study","author":"Chou","year":"2022","journal-title":"Graefe's Arch Clin Exp Ophthalmol = Albr von Graefes Arch fur klin exp Ophthalmol"},{"key":"10.1016\/j.ajo.2025.09.050_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.oret.2024.01.013","article-title":"Image analysis-based machine learning for the diagnosis of retinopathy of prematurity: a meta-analysis and systematic review","author":"Chu","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ajo.2025.09.050_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2024.0045","article-title":"Multinational external validation of autonomous retinopathy of prematurity screening","author":"Coyner","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2025.09.050_bib0024","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ophtha.2019.01.021","article-title":"Plus disease in telemedicine approaches to evaluating acute-phase ROP (e-ROP) study: characteristics, predictors, and accuracy of image grading","volume":"126","author":"Cheng","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.09.050_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaapos.2021.12.006","article-title":"Comparing the diagnostic accuracy of telemedicine utilization versus in-person clinical examination for retinopathy of prematurity in premature infants: a systematic review","author":"Li","year":"2022","journal-title":"J AAPOS"},{"issue":"1","key":"10.1016\/j.ajo.2025.09.050_bib0026","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22964-w","article-title":"Effective field of view of wide-field fundus photography in the Stanford University Network for diagnosis of retinopathy of prematurity (SUNDROP)","volume":"12","author":"Ji","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.ajo.2025.09.050_bib0027","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1111\/aos.14264","article-title":"Automated diagnosis and quantitative analysis of plus disease in retinopathy of prematurity based on deep convolutional neural networks","volume":"98","author":"Mao","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ajo.2025.09.050_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2024.06.006","article-title":"Use of an artificial intelligence-generated vascular severity score improved plus disease diagnosis in retinopathy of prematurity","author":"Coyner","year":"2024","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2025.09.050_bib0029","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jaapos.2005.11.019","article-title":"RetCam imaging for retinopathy of prematurity screening","volume":"10","author":"Wu","year":"2006","journal-title":"J AAPOS"},{"issue":"10","key":"10.1016\/j.ajo.2025.09.050_bib0030","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1097\/IAE.0b013e3181803c14","article-title":"Computer-assisted assessment of plus disease in retinopathy of prematurity using video indirect ophthalmoscopy images","volume":"28","author":"Ahmad","year":"2008","journal-title":"Retina"},{"issue":"12","key":"10.1016\/j.ajo.2025.09.050_bib0031","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2025.09.050_bib0032","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ajo.2025.09.050_bib0033","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.ophtha.2022.06.042","article-title":"A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity","volume":"129","author":"Chang","year":"2022","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2025.09.050_bib0034","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","article-title":"Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan","volume":"118","author":"Wu","year":"2011","journal-title":"Ophthalmology"},{"issue":"32","key":"10.1016\/j.ajo.2025.09.050_bib0035","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000039251","article-title":"Six years follow-up of type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of ranibizumab and bevacizumab: long-term outcomes of intravitreal injection in type 1 ROP","volume":"103","author":"Tung","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.ajo.2025.09.050_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2024.113913","article-title":"Clinical risk factors for retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor injection","volume":"273","author":"Lee","year":"2024","journal-title":"J Pediatr"},{"issue":"8","key":"10.1016\/j.ajo.2025.09.050_bib0037","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.ophtha.2020.12.028","article-title":"Retinal detachment after treatment of retinopathy of prematurity with laser versus intravitreal anti-vascular endothelial growth factor","volume":"128","author":"Barry","year":"2021","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2025.09.050_bib0038","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ophtha.2022.11.012","article-title":"Comparison in retreatments between bevacizumab and ranibizumab intravitreal injections for retinopathy of prematurity: a multicenter study","volume":"130","author":"Patel","year":"2023","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2025.09.050_bib0039","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3928\/23258160-20200702-05","article-title":"SAFER-ROP: updated protocol for anti-VEGF injections for retinopathy of prematurity","volume":"51","author":"Beck","year":"2020","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"3","key":"10.1016\/j.ajo.2025.09.050_bib0040","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4103\/sjopt.sjopt_229_21","article-title":"Anesthesia in retinopathy of prematurity","volume":"36","author":"Alselaimy","year":"2022","journal-title":"Saudi J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.09.050_bib0041","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaapos.2012.11.007","article-title":"Anesthetic and airway management during laser treatment for retinopathy of prematurity: a survey of US ophthalmologists and neonatologists","volume":"17","author":"Klein","year":"2013","journal-title":"J AAPOS"},{"issue":"8","key":"10.1016\/j.ajo.2025.09.050_bib0042","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/sj.eye.6702499","article-title":"Variation in anaesthesia for the laser treatment of retinopathy of prematurity\u2013a survey of ophthalmologists in the UK","volume":"21","author":"Chen","year":"2007","journal-title":"Eye"},{"issue":"6","key":"10.1016\/j.ajo.2025.09.050_bib0043","doi-asserted-by":"crossref","first-page":"860","DOI":"10.4103\/ijo.IJO_325_19","article-title":"Safety and efficacy of 532 nm frequency-doubled Nd-YAG green laser photocoagulation for treatment of retinopathy of prematurity","volume":"67","author":"Singh","year":"2019","journal-title":"Indian J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2025.09.050_bib0044","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s10103-019-02918-x","article-title":"Comparison of Nd:YAG laser (532 nm green) vs diode laser (810 nm) photocoagulation in the treatment of retinopathy of prematurity: an evaluation in terms of complications","volume":"35","author":"Dikci","year":"2020","journal-title":"Lasers Med Sci"},{"issue":"3","key":"10.1016\/j.ajo.2025.09.050_bib0045","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/eye.2015.289","article-title":"Medscape. Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up","volume":"30","author":"Isaac","year":"2016","journal-title":"Eye"},{"issue":"9","key":"10.1016\/j.ajo.2025.09.050_bib0046","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2025.09.050_bib0047","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1007\/s00417-022-05628-3","article-title":"Repeated intravitreal ranibizumab for reactivated retinopathy of prematurity after intravitreal ranibizumab monotherapy: vascular development analysis","volume":"260","author":"Xia","year":"2022","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2025.09.050_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.oret.2022.02.006","article-title":"Time course of retinopathy of prematurity regression and reactivation after treatment with ranibizumab or laser in the RAINBOW trial","author":"Fleck","year":"2022","journal-title":"Ophthalmol Retina"},{"issue":"8","key":"10.1016\/j.ajo.2025.09.050_bib0049","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.09.050_bib0050","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00417-020-04605-y","article-title":"A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series","volume":"258","author":"Martinez-Castellanos","year":"2020","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2025.09.050_bib0051","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/ICU.0000000000000786","article-title":"Description and management of retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor therapy","volume":"32","author":"Valikodath","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2025.09.050_bib0052","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223972","article-title":"Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment","volume":"14","author":"Chang","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ajo.2025.09.050_bib0053","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.785292","article-title":"Characteristics of eyes developing retinal detachment after anti-vascular endothelial growth factor therapy for retinopathy of prematurity","volume":"10","author":"Kondo","year":"2022","journal-title":"Front Pediatr"},{"issue":"3","key":"10.1016\/j.ajo.2025.09.050_bib0054","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3928\/23258160-20160229-12","article-title":"Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab","volume":"47","author":"Snyder","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ajo.2025.09.050_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaapos.2021.02.004","article-title":"Very late-onset reactivation of retinopathy of prematurity post anti-VEGF bevacizumab treatment for type 1 ROP: a case report","author":"Taylor","year":"2021","journal-title":"J AAPOS"},{"issue":"6","key":"10.1016\/j.ajo.2025.09.050_bib0056","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.oret.2019.12.015","article-title":"Late-onset retinal findings and complications in untreated retinopathy of prematurity","volume":"4","author":"Hamad","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"10.1016\/j.ajo.2025.09.050_bib0057","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.oret.2022.07.005","article-title":"Late vitreoretinal complications of regressed retinopathy of prematurity: retinal break, vitreous hemorrhage, and retinal detachment","volume":"7","author":"Hsu","year":"2023","journal-title":"Ophthalmol Retina"},{"issue":"10","key":"10.1016\/j.ajo.2025.09.050_bib0058","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.ophtha.2004.02.005","article-title":"Involution of threshold retinopathy of prematurity after diode laser photocoagulation","volume":"111","author":"Coats","year":"2004","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2025.09.050_bib0059","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jaapos.2011.12.157","article-title":"Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children","volume":"16","author":"Blair","year":"2012","journal-title":"J AAPOS"},{"issue":"7","key":"10.1016\/j.ajo.2025.09.050_bib0060","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1097\/IAE.0b013e31820d3f70","article-title":"Management of avascular peripheral retina in older prematurely born infants","volume":"31","author":"Ho","year":"2011","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.ajo.2025.09.050_bib0061","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.ophtha.2016.06.055","article-title":"Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity","volume":"123","author":"Toy","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2025.09.050_bib0062","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","article-title":"Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity","volume":"38","author":"Garcia Gonzalez","year":"2018","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.ajo.2025.09.050_bib0063","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3928\/01913913-20190501-01","article-title":"Persistent avascular retina in infants with a history of type 2 retinopathy of prematurity: to treat or not to treat?","volume":"56","author":"Al-Taie","year":"2019","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"5","key":"10.1016\/j.ajo.2025.09.050_bib0064","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jcjo.2020.05.017","article-title":"Fluorescein angiographic features post-intravitreal bevacizumab for retinopathy of prematurity: can they support rescue laser photocoagulation to the avascular retina","volume":"55","author":"Gonzalez","year":"2020","journal-title":"Can J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2025.09.050_bib0065","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.oret.2020.02.001","article-title":"Reactivation of retinopathy of prematurity in adults and adolescents","volume":"4","author":"Uner","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"10.1016\/j.ajo.2025.09.050_bib0066","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.oret.2019.01.016","article-title":"Fluorescein angiography in retinopathy of prematurity: comparison of infants treated with bevacizumab to those with spontaneous regression","volume":"3","author":"Mansukhani","year":"2019","journal-title":"Ophthalmol Retina"},{"issue":"8","key":"10.1016\/j.ajo.2025.09.050_bib0067","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/s41433-021-01694-9","article-title":"Fundus fluorescein angiography in retinopathy of prematurity","volume":"36","author":"Hans","year":"2022","journal-title":"Eye"},{"issue":"4","key":"10.1016\/j.ajo.2025.09.050_bib0068","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/IAE.0000000000001996","article-title":"Fluorescein angiographic evaluation of peripheral retinal vasculature after primary intravitreal ranibizumab for retinopathy of prematurity","volume":"39","author":"Harper 3rd","year":"2019","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.ajo.2025.09.050_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100281","article-title":"Persistent vascular anomalies in retinopathy of prematurity children: ultrawide-field fluorescein angiography findings until school age","volume":"3","author":"Ling","year":"2023","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.ajo.2025.09.050_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaapos.2021.08.227","article-title":"Prevalence of persistent avascular retina in untreated children with a history of retinopathy of prematurity screening","author":"Hanif","year":"2021","journal-title":"J AAPOS"},{"key":"10.1016\/j.ajo.2025.09.050_bib0071","doi-asserted-by":"crossref","DOI":"10.1038\/s41433-023-02921-1","article-title":"Retinopathy of prematurity screening: prevalence and risk factors of ophthalmic complications in non-treated preterm infants","author":"Strelnikov","year":"2024","journal-title":"Eye"},{"issue":"9","key":"10.1016\/j.ajo.2025.09.050_bib0072","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/bjo.84.9.963","article-title":"Long term follow up of premature infants: detection of strabismus, amblyopia, and refractive errors","volume":"84","author":"Schalij-Delfos","year":"2000","journal-title":"The Br J Ophthalmol."},{"issue":"12","key":"10.1016\/j.ajo.2025.09.050_bib0073","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1167\/iovs.10-5234","article-title":"Long-term evaluation of refractive status and optical components in eyes of children born prematurely","volume":"51","author":"Chen","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.ajo.2025.09.050_bib0074","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1167\/tvst.10.4.14","article-title":"Longitudinal development of refractive error in children treated with intravitreal bevacizumab or laser for retinopathy of prematurity","volume":"10","author":"Simmons","year":"2021","journal-title":"Transl Vis Sci Technol"},{"issue":"12","key":"10.1016\/j.ajo.2025.09.050_bib0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225643","article-title":"Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: a meta-analysis and systematic review","volume":"14","author":"Tan","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ajo.2025.09.050_bib0076","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-042384","article-title":"Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis","volume":"11","author":"Kong","year":"2021","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.ajo.2025.09.050_bib0077","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/archophthalmol.2011.179","article-title":"Effect of age on response to amblyopia treatment in children","volume":"129","author":"Holmes","year":"2011","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.09.050_bib0078","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.ajo.2025.09.050_bib0079","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity","volume":"256","author":"Huang","year":"2018","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmo"},{"issue":"11","key":"10.1016\/j.ajo.2025.09.050_bib0080","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.ophtha.2019.03.048","article-title":"Neurodevelopmental outcomes after intravitreal bevacizumab therapy for retinopathy of prematurity: a prospective case-control study","volume":"126","author":"Fan","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.09.050_bib0081","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ajo.2021.06.034","article-title":"Cognitive outcomes following intravitreal bevacizumab for retinopathy of prematurity: 4- to 6-year outcomes in a prospective cohort","volume":"234","author":"Chou","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.09.050_bib0082","doi-asserted-by":"crossref","DOI":"10.1097\/IAE.0000000000004222","article-title":"Administering intravitreal bevacizumab for retinopathy of prematurity: 8-year cognitive outcomes in a prospective cohort","author":"Wu","year":"2024","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.ajo.2025.09.050_bib0083","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ophtha.2020.11.012","article-title":"Neurodevelopmental outcomes after bevacizumab treatment for retinopathy of prematurity: a meta-analysis","volume":"128","author":"Tsai","year":"2021","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2025.09.050_bib0084","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jamaophthalmol.2023.4787","article-title":"Neurodevelopmental outcomes in infants screened for retinopathy of prematurity","volume":"141","author":"Karmouta","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2025.09.050_bib0085","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S2352-4642(21)00195-4","article-title":"2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial","volume":"5","author":"Marlow","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"issue":"4","key":"10.1016\/j.ajo.2025.09.050_bib0086","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.8383","article-title":"Intravitreal aflibercept vs laser therapy for retinopathy of prematurity: two-year efficacy and safety outcomes in the nonrandomized controlled trial FIREFLEYE next","volume":"7","author":"Stahl","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2025.09.050_bib0087","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.4103\/ijo.IJO_1827_19","article-title":"Operational guidelines for ROP in India: a summary","volume":"68","author":"Shukla","year":"2020","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.09.050_bib0088","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1002\/hsr2.219","article-title":"How to prevent ROP in preterm infants in Indonesia?","volume":"4","author":"Siswanto","year":"2021","journal-title":"Health Sci Rep"},{"issue":"10","key":"10.1016\/j.ajo.2025.09.050_bib0089","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/jpc.12940","article-title":"Retinopathy of prematurity: New Zealand recommendations for case detection and treatment","volume":"51","author":"Dai","year":"2015","journal-title":"J Paediatr Child Health"},{"issue":"3","key":"10.1016\/j.ajo.2025.09.050_bib0090","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.sjopt.2018.07.007","article-title":"Practical guidelines for screening and treatment of retinopathy of prematurity in Saudi Arabia","volume":"32","author":"Al Amro","year":"2018","journal-title":"Saudi J Ophthalmol"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2025.09.050_bib0091","first-page":"S151","article-title":"Turkish Neonatal and Turkish Ophthalmology Societies consensus guideline on the retinopathy of prematurity","volume":"53","author":"Koc","year":"2018","journal-title":"Turk Pediatri Ars"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942500529X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942500529X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T21:23:45Z","timestamp":1764969825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293942500529X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":91,"alternative-id":["S000293942500529X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.09.050","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Retinopathy of Prematurity in the Anti-VEGF Era: Consensus and Recommendations From the Taiwan Pediatric Retina (TPR) Group","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.09.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}